DarioHealth (DRIO) Stock Forecast, Price Target & Predictions
DRIO Stock Forecast
DarioHealth stock forecast is as follows: an average price target of $10.75 (represents a 1033.97% upside from DRIO’s last price of $0.95) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
DRIO Price Target
The average price target for DarioHealth (DRIO) is $10.75 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $7.50. This represents a potential 1033.97% upside from DRIO's last price of $0.95.
DRIO Analyst Ratings
According to 3 Wall Street analysts, DarioHealth's rating consensus is 'Buy'. The analyst rating breakdown for DRIO stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DarioHealth Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 16, 2022 | - | Industrial Alliance Securities | $7.50 | $5.18 | 44.79% | 691.14% |
| Aug 18, 2022 | - | Cowen & Co. | $14.00 | $5.49 | 155.01% | 1376.79% |
| May 16, 2022 | - | Cowen & Co. | $18.00 | $6.33 | 184.36% | 1798.73% |
The latest DarioHealth stock forecast, released on Nov 16, 2022 by Industrial Alliance Securities company, set a price target of $7.50, which represents a 44.79% increase from the stock price at the time of the forecast ($5.18), and a 691.14% increase from DRIO last price ($0.95).
DarioHealth Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.95 | $0.95 | $0.95 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of DarioHealth stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DarioHealth's last price of $0.95. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Nov 16, 2022 | Alliance Global Partners | Buy | Buy | Hold |
| Aug 18, 2022 | Aegis Capital | Buy | Buy | Hold |
| Aug 18, 2022 | Cowen & Co. | Outperform | Outperform | Hold |
| May 16, 2022 | Aegis Capital | Buy | Buy | Hold |
| May 16, 2022 | Cowen & Co. | Outperform | Outperform | Hold |
| May 13, 2022 | Alliance Global Partners | - | Buy | Upgrade |
DarioHealth's last stock rating was published by Cowen & Co. on Jun 14, 2024. The company gave DRIO a "Buy" rating, the same as its previous rate.
DarioHealth Financial Forecast
DarioHealth Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $3.62M | $3.52M | $6.15M | $7.07M | $6.81M | $6.61M | $6.18M | $8.06M | - | $1.21M | $5.26M | $3.60M | $2.08M | $2.04M | $1.79M | $1.67M | $1.80M | $1.87M |
| Avg Forecast | $13.11M | $12.82M | $12.55M | $11.78M | $10.23M | $9.90M | $9.58M | $9.27M | $7.84M | $7.40M | $7.92M | $6.76M | $3.78M | $5.42M | $6.50M | $6.70M | $6.71M | $6.29M | $8.25M | $6.82M | $6.02M | $5.77M | $5.14M | $4.00M | $2.11M | $1.95M | $1.55M | $1.75M | $2.05M | $1.93M |
| High Forecast | $14.62M | $14.30M | $13.99M | $13.13M | $11.41M | $11.03M | $10.68M | $10.34M | $8.74M | $8.25M | $8.83M | $7.54M | $4.22M | $6.04M | $7.24M | $7.47M | $7.48M | $7.02M | $8.50M | $7.03M | $6.20M | $5.95M | $5.30M | $4.12M | $2.17M | $2.01M | $1.60M | $1.80M | $2.11M | $1.99M |
| Low Forecast | $11.70M | $11.44M | $11.19M | $10.50M | $9.13M | $8.83M | $8.54M | $8.27M | $6.99M | $6.60M | $7.06M | $6.03M | $3.37M | $4.83M | $5.80M | $5.98M | $5.99M | $5.61M | $8.01M | $6.62M | $5.84M | $5.60M | $4.99M | $3.88M | $2.04M | $1.90M | $1.51M | $1.70M | $1.99M | $1.88M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 13 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.96% | 0.65% | 0.95% | 1.05% | 1.01% | 1.05% | 0.75% | 1.18% | - | 0.21% | 1.02% | 0.90% | 0.99% | 1.05% | 1.15% | 0.95% | 0.88% | 0.97% |
DarioHealth's average Quarter revenue forecast for Mar 24 based on 0 analysts is $6.76M, with a low forecast of $6.03M, and a high forecast of $7.54M. DRIO's average Quarter revenue forecast represents a 86.92% increase compared to the company's last Quarter revenue of $3.62M (Dec 23).
DarioHealth EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 13 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-12.76M | $-15.55M | $-14.02M | $-10.91M | $-7.51M | $-13.35M | $-16.15M | $-14.82M | $-21.66M | $2.60M | $-16.96M | $-14.53M | $-8.95M | $-6.50M | $-3.96M | $-9.85M | $-4.29M | $-2.73M |
| Avg Forecast | $-13.11M | $-12.82M | $-12.55M | $-11.78M | $-10.23M | $-9.90M | $-9.58M | $-9.27M | $-7.84M | $-7.40M | $-7.92M | $-6.76M | $-3.78M | $-5.42M | $-6.50M | $-6.70M | $-6.71M | $2.13M | $-8.25M | $-18.32M | $-6.02M | $-5.77M | $-5.14M | $-16.20M | $-2.11M | $-1.95M | $-1.55M | $-7.06M | $-2.05M | $-1.93M |
| High Forecast | $-11.70M | $-11.44M | $-11.19M | $-10.50M | $-9.13M | $-8.83M | $-8.54M | $-8.27M | $-6.99M | $-6.60M | $-7.06M | $-6.03M | $-3.37M | $-4.83M | $-5.80M | $-5.98M | $-5.99M | $2.55M | $-8.01M | $-14.66M | $-5.84M | $-5.60M | $-4.99M | $-12.96M | $-2.04M | $-1.90M | $-1.51M | $-5.65M | $-1.99M | $-1.88M |
| Low Forecast | $-14.62M | $-14.30M | $-13.99M | $-13.13M | $-11.41M | $-11.03M | $-10.68M | $-10.34M | $-8.74M | $-8.25M | $-8.83M | $-7.54M | $-4.22M | $-6.04M | $-7.24M | $-7.47M | $-7.48M | $1.70M | $-8.50M | $-21.98M | $-6.20M | $-5.95M | $-5.30M | $-19.44M | $-2.17M | $-2.01M | $-1.60M | $-8.48M | $-2.11M | $-1.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.37% | 2.87% | 2.16% | 1.63% | 1.12% | -6.27% | 1.96% | 0.81% | 3.60% | -0.45% | 3.30% | 0.90% | 4.25% | 3.33% | 2.55% | 1.39% | 2.09% | 1.41% |
0 analysts predict DRIO's average Quarter EBITDA for Dec 21 to be $-6.02M, with a high of $-5.84M and a low of $-6.20M. This is -331.57% lower than DarioHealth's previous annual EBITDA (Sep 21) of $2.60M.
DarioHealth Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 13 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-12.00M | $16.90M | $18.28M | $12.41M | $-12.62M | $-16.69M | $-18.03M | $-15.96M | $32.73M | - | $-17.77M | $-14.97M | $-9.00M | $-6.55M | $-4.01M | $-9.89M | $-4.17M | $-2.81M |
| Avg Forecast | $-8.36M | $-8.36M | $-8.76M | $-9.16M | $-9.96M | $-9.96M | $-9.96M | $-10.75M | $-7.44M | $-8.63M | $-17.72M | $-11.75M | $-15.53M | $-20.71M | $-20.47M | $-19.84M | $-24.30M | $-30.39M | $-30.04M | $-19.56M | $-46.09M | $-39.32M | $-34.60M | $-16.69M | $-34.19M | $-27.22M | $-55.66M | $-7.10M | $-40.63M | $-71.70M |
| High Forecast | $-7.19M | $-7.19M | $-7.53M | $-7.87M | $-8.56M | $-8.56M | $-8.56M | $-9.24M | $-6.39M | $-7.42M | $-15.23M | $-10.10M | $-13.35M | $-17.80M | $-17.60M | $-17.05M | $-20.88M | $-26.12M | $-28.88M | $-15.65M | $-44.31M | $-37.80M | $-33.27M | $-13.35M | $-32.87M | $-26.17M | $-53.51M | $-5.68M | $-39.06M | $-68.92M |
| Low Forecast | $-9.61M | $-9.61M | $-10.07M | $-10.53M | $-11.44M | $-11.44M | $-11.44M | $-12.36M | $-8.55M | $-9.92M | $-20.37M | $-13.50M | $-17.85M | $-23.80M | $-23.53M | $-22.80M | $-27.92M | $-34.92M | $-31.23M | $-23.48M | $-47.91M | $-40.87M | $-35.97M | $-20.03M | $-35.54M | $-28.29M | $-57.86M | $-8.51M | $-42.23M | $-74.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | -0.82% | -0.89% | -0.63% | 0.52% | 0.55% | 0.60% | 0.82% | -0.71% | - | 0.51% | 0.90% | 0.26% | 0.24% | 0.07% | 1.39% | 0.10% | 0.04% |
DarioHealth's average Quarter net income forecast for Dec 23 is $-15.53M, with a range of $-17.85M to $-13.35M. DRIO's average Quarter net income forecast represents a -191.90% decrease compared to the company's last Quarter net income of $16.90M (Sep 23).
DarioHealth SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 13 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $10.02M | $10.49M | $10.87M | $10.41M | $6.96M | $11.57M | $14.36M | $13.93M | - | $17.82M | $15.77M | $12.75M | $8.19M | $6.20M | $3.93M | $9.66M | $4.18M | $2.81M |
| Avg Forecast | $33.36M | $32.63M | $31.92M | $29.96M | $26.04M | $25.18M | $24.36M | $23.59M | $19.95M | $18.82M | $20.14M | $17.20M | $9.62M | $13.79M | $16.53M | $17.06M | $17.08M | $16.01M | $20.99M | $17.35M | $15.31M | $14.69M | $13.09M | $10.17M | $5.36M | $4.97M | $3.96M | $4.45M | $5.22M | $4.92M |
| High Forecast | $37.19M | $36.38M | $35.58M | $33.40M | $29.03M | $28.07M | $27.16M | $26.30M | $22.24M | $20.98M | $22.45M | $19.17M | $10.72M | $15.38M | $18.43M | $19.02M | $19.04M | $17.85M | $21.63M | $17.88M | $15.77M | $15.13M | $13.49M | $10.48M | $5.52M | $5.12M | $4.08M | $4.59M | $5.37M | $5.07M |
| Low Forecast | $29.75M | $29.10M | $28.47M | $26.72M | $23.22M | $22.46M | $21.73M | $21.04M | $17.79M | $16.79M | $17.96M | $15.34M | $8.58M | $12.30M | $14.75M | $15.21M | $15.23M | $14.28M | $20.37M | $16.84M | $14.85M | $14.25M | $12.70M | $9.87M | $5.20M | $4.82M | $3.84M | $4.32M | $5.06M | $4.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.76% | 0.66% | 0.61% | 0.41% | 0.72% | 0.68% | 0.80% | - | 1.21% | 1.20% | 1.25% | 1.53% | 1.25% | 0.99% | 2.17% | 0.80% | 0.57% |
DarioHealth's average Quarter SG&A projection for Mar 24 is $17.20M, based on 0 Wall Street analysts, with a range of $15.34M to $19.17M. The forecast indicates a 71.56% rise compared to DRIO last annual SG&A of $10.02M (Dec 23).
DarioHealth EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - | - | - | - | - | - | 9 | 9 | 9 | 9 | 13 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $0.49 | $0.58 | $0.45 | $-0.53 | $-0.73 | $-0.80 | $-0.81 | $2.09 | $-1.18 | $-0.99 | $-0.92 | $-1.23 | $-0.71 | $-0.68 | $-1.57 | $-1.35 | $-1.20 |
| Avg Forecast | $-0.21 | $-0.21 | $-0.22 | $-0.23 | $-0.25 | $-0.25 | $-0.25 | $-0.27 | $-0.19 | $-0.22 | $-0.45 | $-0.29 | $-0.39 | $-0.52 | $-0.51 | $-0.50 | $-0.61 | $-0.76 | $-0.75 | $-0.96 | $-1.16 | $-0.99 | $-0.87 | $-0.80 | $-0.86 | $-0.68 | $-1.40 | $-0.75 | $-1.02 | $-1.80 |
| High Forecast | $-0.18 | $-0.18 | $-0.19 | $-0.20 | $-0.21 | $-0.21 | $-0.21 | $-0.23 | $-0.16 | $-0.19 | $-0.38 | $-0.25 | $-0.34 | $-0.45 | $-0.44 | $-0.43 | $-0.52 | $-0.66 | $-0.73 | $-0.92 | $-1.11 | $-0.95 | $-0.84 | $-0.76 | $-0.83 | $-0.66 | $-1.34 | $-0.72 | $-0.98 | $-1.73 |
| Low Forecast | $-0.24 | $-0.24 | $-0.25 | $-0.26 | $-0.29 | $-0.29 | $-0.29 | $-0.31 | $-0.21 | $-0.25 | $-0.51 | $-0.34 | $-0.45 | $-0.60 | $-0.59 | $-0.57 | $-0.70 | $-0.88 | $-0.78 | $-0.99 | $-1.20 | $-1.03 | $-0.90 | $-0.83 | $-0.89 | $-0.71 | $-1.45 | $-0.78 | $-1.06 | $-1.87 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | -0.94% | -1.13% | -0.90% | 0.87% | 0.96% | 1.06% | 0.85% | -1.81% | 1.20% | 1.14% | 1.16% | 1.43% | 1.04% | 0.49% | 2.09% | 1.32% | 0.67% |
According to 1 Wall Street analysts, DarioHealth's projected average Quarter EPS for Dec 23 is $-0.39, with a low estimate of $-0.45 and a high estimate of $-0.34. This represents a -179.59% decrease compared to DRIO previous annual EPS of $0.49 (Sep 23).
DarioHealth Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| STIM | Neuronetics | $0.73 | $8.00 | 995.89% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
DRIO Forecast FAQ
Is DarioHealth a good buy?
Yes, according to 3 Wall Street analysts, DarioHealth (DRIO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of DRIO's total ratings.
What is DRIO's price target?
DarioHealth (DRIO) average price target is $10.75 with a range of $7.5 to $14, implying a 1033.97% from its last price of $0.948. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DarioHealth stock go up soon?
According to Wall Street analysts' prediction for DRIO stock, the company can go up by 1033.97% (from the last price of $0.948 to the average price target of $10.75), up by 1376.79% based on the highest stock price target, and up by 691.14% based on the lowest stock price target.
Can DarioHealth stock reach $1?
DRIO's average twelve months analyst stock price target of $10.75 supports the claim that DarioHealth can reach $1 in the near future.
What are DarioHealth's analysts' financial forecasts?
DarioHealth's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $38.98M (high $43.46M, low $34.76M), average EBITDA is $-38.978M (high $-34.764M, low $-43.455M), average net income is $-40.627M (high $-34.917M, low $-46.694M), average SG&A $99.16M (high $110.55M, low $88.44M), and average EPS is $-1.02 (high $-0.877, low $-1.172). DRIO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $50.26M (high $56.03M, low $44.83M), average EBITDA is $-50.261M (high $-44.827M, low $-56.034M), average net income is $-34.653M (high $-29.783M, low $-39.827M), average SG&A $127.87M (high $142.55M, low $114.04M), and average EPS is $-0.87 (high $-0.748, low $-1).
Did the DRIO's actual financial results beat the analysts' financial forecasts?
Based on DarioHealth's last annual report (Dec 2023), the company's revenue was $20.35M, which missed the average analysts forecast of $22.4M by -9.16%. Apple's EBITDA was $-56.189M, beating the average prediction of $-22.405M by 150.79%. The company's net income was $63.51M, missing the average estimation of $-76.555M by -182.96%. Apple's SG&A was $41.92M, missing the average forecast of $57M by -26.45%. Lastly, the company's EPS was $1.93, missing the average prediction of $-1.922 by -200.42%. In terms of the last quarterly report (Dec 2023), DarioHealth's revenue was $3.62M, missing the average analysts' forecast of $3.78M by -4.36%. The company's EBITDA was $-12.756M, beating the average prediction of $-3.781M by 237.37%. DarioHealth's net income was $-12.001M, missing the average estimation of $-15.534M by -22.74%. The company's SG&A was $10.02M, beating the average forecast of $9.62M by 4.20%. Lastly, the company's EPS was $-0.44, beating the average prediction of $-0.39 by 12.82%